REFINE-Lung implements a novel multi-arm randomised trial design to address possible immunotherapy overtreatment. (2023)
Attributed to:
Method - Design
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s1470-2045(23)00095-5
PubMed Identifier: 37142383
Publication URI: http://europepmc.org/abstract/MED/37142383
Type: Journal Article/Review
Volume: 24
Parent Publication: The Lancet. Oncology
Issue: 5
ISSN: 1470-2045